(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(0.11%) $82.72
(1.03%) $2.05
(-0.43%) $2 347.50
(-0.85%) $27.43
(-0.20%) $959.60
(-0.20%) $0.933
(-0.36%) $10.98
(-0.53%) $0.796
(1.56%) $93.31
3.13% $ 22.05
@ $35.38
Ausgestellt: 21 Mär 2024 @ 19:07
Rendite: -37.68%
Vorheriges Signal: Mär 20 - 16:15
Vorheriges Signal:
Rendite: 1.94 %
Live Chart Being Loaded With Signals
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States...
Stats | |
---|---|
Tagesvolumen | 884 832 |
Durchschnittsvolumen | 1.53M |
Marktkapitalisierung | 1.80B |
EPS | $0 ( 2024-02-27 ) |
Nächstes Ertragsdatum | ( $-1.450 ) 2024-05-08 |
Last Dividend | $0.225 ( 2014-02-04 ) |
Next Dividend | $0 ( N/A ) |
P/E | -12.82 |
ATR14 | $0.0270 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-26 | Burrell Terry-ann | Buy | 12 500 | Common Stock |
2024-04-26 | Burrell Terry-ann | Buy | 25 000 | Stock Option (Right to Buy) |
2024-04-01 | Simon Amy | Sell | 7 157 | Common Stock |
2024-04-02 | Simon Amy | Sell | 16 530 | Common Stock |
2024-04-01 | Bellon Christine | Sell | 3 401 | Common Stock |
INSIDER POWER |
---|
-11.08 |
Last 98 transactions |
Buy: 1 537 714 | Sell: 1 873 404 |
Volumen Korrelation
Beam Therapeutics Inc Korrelation
10 Am meisten positiv korreliert | |
---|---|
TUEM | 0.951 |
TWST | 0.942 |
SGMO | 0.93 |
CSSE | 0.929 |
ROST | 0.927 |
MDRX | 0.926 |
GRPN | 0.924 |
RKDA | 0.924 |
HMST | 0.923 |
AFIB | 0.923 |
10 Am meisten negativ korreliert | |
---|---|
WIRE | -0.933 |
CPTA | -0.928 |
TYHT | -0.928 |
ZGNX | -0.926 |
HTBI | -0.92 |
VC | -0.92 |
PAE | -0.919 |
SGEN | -0.919 |
RAM | -0.916 |
EBSB | -0.91 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Beam Therapeutics Inc Korrelation - Währung/Rohstoff
Beam Therapeutics Inc Finanzdaten
Annual | 2023 |
Umsatz: | $377.71M |
Bruttogewinn: | $357.70M (94.70 %) |
EPS: | $-1.720 |
FY | 2023 |
Umsatz: | $377.71M |
Bruttogewinn: | $357.70M (94.70 %) |
EPS: | $-1.720 |
FY | 2022 |
Umsatz: | $60.92M |
Bruttogewinn: | $38.34M (62.94 %) |
EPS: | $-3.76 |
FY | 2021 |
Umsatz: | $51.84M |
Bruttogewinn: | $51.84M (100.00 %) |
EPS: | $-5.77 |
Financial Reports:
No articles found.
Beam Therapeutics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.190 | 2011-11-07 |
Last Dividend | $0.225 | 2014-02-04 |
Next Dividend | $0 | N/A |
Payout Date | 2014-03-03 | |
Next Payout Date | N/A | |
# dividends | 10 | -- |
Total Paid Out | $2.16 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.6 | -- |
Div. Sustainability Score | 1.443 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.318 | 1.500 | -6.36 | -9.54 | [0 - 0.5] |
returnOnAssetsTTM | -0.0823 | 1.200 | -2.74 | -3.29 | [0 - 0.3] |
returnOnEquityTTM | -0.144 | 1.500 | -2.71 | -4.07 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.89 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.79 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.12 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.119 | -1.500 | 8.02 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -5.10 | 1.000 | -3.00 | -3.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.845 | 2.00 | -0.615 | -1.230 | [0 - 30] |
freeCashFlowPerShareTTM | -2.26 | 2.00 | -1.131 | -2.26 | [0 - 20] |
debtEquityRatioTTM | 0.176 | -1.500 | 9.29 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.928 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.467 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.862 | 1.000 | -5.90 | -5.90 | [0.2 - 2] |
assetTurnoverTTM | 0.259 | 0.800 | -1.608 | -1.287 | [0.5 - 2] |
Total Score | 1.443 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -14.39 | 1.000 | -1.555 | 0 | [1 - 100] |
returnOnEquityTTM | -0.144 | 2.50 | -1.744 | -4.07 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.26 | 2.00 | -0.754 | -2.26 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.845 | 2.00 | -0.615 | -1.230 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.395 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.37 |
Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.